mTORC1 is well-established to promote cancer progression through induction of protein synthesis, cell growth, cell proliferation, angiogenesis and suppression of autophagy [71], and together with PI3K, which along with mTOR, is activated downstream of HER2 signalling is a known resistance mechanism of T-DM1 [21, 72]. The gene discussed is ERBB2; the disease is cancer.